โ Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting...
โ Additional positive data from the Companyโs completed Phase 1 clinical trial evaluating ENTR-601-44...
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.